Emergent Biosolut Stock Cash And Equivalents
| ER4 Stock | EUR 8.22 0.24 2.84% |
EMERGENT BIOSOLUT fundamentals help investors to digest information that contributes to EMERGENT BIOSOLUT's financial success or failures. It also enables traders to predict the movement of EMERGENT Stock. The fundamental analysis module provides a way to measure EMERGENT BIOSOLUT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EMERGENT BIOSOLUT stock.
EMERGENT |
EMERGENT BIOSOLUT Company Cash And Equivalents Analysis
EMERGENT BIOSOLUT's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, EMERGENT BIOSOLUT has 0.0 in Cash And Equivalents. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
EMERGENT Fundamentals
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B | |||
| Total Asset | 3.17 B | |||
| Z Score | 2.4 | |||
| Net Asset | 3.17 B |
About EMERGENT BIOSOLUT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EMERGENT BIOSOLUT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EMERGENT BIOSOLUT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EMERGENT BIOSOLUT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.